Hypertension – efficient polypill therapy Review article

Main Article Content

Juliusz Rawdanowicz

Abstract

The incidence of hypertension varies from 30% to 70% of the population. By using the guidelines of hypertension treatment efficacy steadily growing over the years, but it still does not exceed 50%. Treatment provided in accordance with evidence-based medicine is much better for patients because synergism of certain drugs stronger reduces blood pressure, prevents the development of complications and reduces the overall risk. ACE inhibitors and calcium antagonists used in combinations are the best documented beneficial effects. Used for approximately a decade of multi-tablet gains a better press, evidence of effectiveness, improves compliance and what is more this therapy seem to cause far fewer side effects in comparison to conventional multidrug therapy.

Article Details

How to Cite
Rawdanowicz , J. (2012). Hypertension – efficient polypill therapy. Medycyna Faktow (J EBM), 5(2(15), 46-50. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2465
Section
Articles

References

1. Yoon S.S., Ostchega Y., Louis T.: Recent Trends in the Prevalence of High Blood Pressure and its Treatment and Control, 1999–2008. NCHS Data Brief No. 48 October 2010.
2. Sznajderman M., Januszewicz W.: Antagoniści wapnia. W: Nadciśnienie tętnicze. Januszewicz A., Januszewicz W., Szczepańska-Sadowska E., Sznajderman M. (red.). Medycyna Praktyczna, Kraków 2007: 1067-1072.
3. Heran B.S., Wong M.M.Y., Heran I.K., Wright J.M.: Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension (Review) Cochrane Database of Systematic Reviews 2008; Issue 4: Art. No CD003823.
4. Wald N.J., Law M.R.: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 28(326): 1419.
5. Januszewicz A., Prejbisz A.: Leczenie skojarzone oparte na antagoniście receptora angiotensyny II – miejsce preparatów złożonych. Terapia 2007; XV(7-8): 89-97.
6. Páll D., Katona E., Juhász M., Paragh G.: Prevention of target organ damage with modern antihypertensive agents. Orv. Hetil. 2006; 147(32): 1505-11.
7. Cappuccio F.P., Markandu N.D., Singer D.R., MacGregor G.A.: Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J. Hypertens. 1993; 11(8): 839-47.
8. Bertrand M., Mourad J.J., Fox K. et al.: Effect of ACE Inhibitors and angiotensin II receptor blockers on all-cause mortality in hypertension trials. Journal of Hypertension 2011; 29(e-Supplement A): e31.
9. Wright J.T. Jr., Dunn J.K., Cutler J.A. et al.: GB Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293(13): 1595-608.
10. Davidovich I.M., Petrichko T.A.: [Combined therapy with amlodipin and lisinopril in arterial hypertension: efficacy of a low-dose combination]. Ter. Arkh. 2006; 78(5): 65-8.
11. Shevchenko O.P., Praskurnichiĭ E.A., Savel’eva S.A.: [Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome]. Ter. Arkh. 2008; 80(4): 54-9.
12. Arslanagić A., Bajraktarević A.: [The effect of lisinopril and amlodipine treatment on left ventricular hypertrophy in hypertensive patients]. Med. Arh. 2006; 60(6 Suppl. 2): 71-3.
13. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22(7): 1309-16.
14. Farsang C., Ábrahám G., Kovács P. et al.: The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS study). Hypertonia Es Nephrologia 2009; 13(3):81-87.